Cancer Treatment Clinical Trials

A listing of Cancer Treatment medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 224 clinical trials
Study of Ulixertinib for Patients With Advanced Malignancies Harboring MEK or Atypical BRAF Alterations

This BVD-523-ABC study builds on the safety and clinical activity experience of previous studies that have evaluated ulixertinib as a novel targeted cancer treatment in cohorts of patients with

  • 0 views
  • 11 Aug, 2022
  • 23 locations
Alberta Cancer Exercise Hybrid Effectiveness-Implementation Study (ACE)

cancer treatment) while preventing the development of secondary cancers.

cancer treatment
primary cancer
  • 16 views
  • 08 Aug, 2022
  • 2 locations
A Phase III, Randomized, Open-Label Study of Pralsetinib Versus Standard of Care for First-Line Treatment of RET Fusion-Positive, Metastatic Non-Small Cell Lung Cancer (AcceleRET-Lung)

NSCLC who have not previously received systemic anticancer therapy for metastatic disease. Participants who have centrally confirmed progressive disease on the control arm have the option to crossover

pemetrexed
metastatic non-small cell lung cancer
metastasis
lung cancer
carboplatin
  • 54 views
  • 18 Sep, 2022
  • 93 locations
Tusamitamab Ravtansine in NSQ NSCLC Participants With Negative or Moderate CEACAM5 Expression Tumors and High Circulating CEA (CARMEN-LC06)

ravtansine as monotherapy every two weeks (Q2W) until disease progression, unacceptable adverse event (AE), initiation of a new anticancer therapy, or the participant's or investigator's decision to stop the

  • 135 views
  • 05 Aug, 2022
  • 19 locations
A Phase 2 Study of TAS-120 in Metastatic Breast Cancers Harboring Fibroblast Growth Factor Receptor (FGFR) Amplifications

conventional therapies to treat their breast cancer, or who are not able to tolerate certain cancer therapies. This study will also evaluate the safety of taking futibatinib, or futibatinib and fulvestrant, by

estrogen
neutrophil count
cancer chemotherapy
liver metastasis
estrogen receptor
  • 76 views
  • 14 Sep, 2022
  • 26 locations
Enhanced, EHR-Facilitated Cancer Symptom Control (E2C2) Trial (E2C2)

quality of life, symptom severity, and adherence to cancer treatment, and may also reduce need for acute care.

depression
sleep disturbances
sleep problem
depressed mood
anxiety
  • 31 views
  • 20 Sep, 2022
  • 1 location
Implementation and Evaluation of an Expanded Bilingual Electronic Symptom Management Program Across a Multi-site, Fully-integrated Comprehensive Cancer Center (NU IMPACT)

Cancer, and cancer treatment, cause many symptoms that can negatively affect quality of life. Despite the development of improved symptom management interventions and several evidenceand

  • 0 views
  • 14 Sep, 2022
  • 1 location
A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatments and Combinations in Patients With Urothelial Carcinoma (MORPHEUS-UC)

minimal clinical activity or unacceptable toxicity, or modify the participant population (e.g., with regard to prior anti-cancer treatment or biomarker status). Participants in the mUC Cohort who

combinations
atezolizumab
niraparib
measurable disease
gemcitabine
  • 13 views
  • 19 Sep, 2022
  • 33 locations
NAVIGATE - Improving Survival in Vulnerable Lung Cancer Patients Through Nurse Navigation, Symptom Monitoring and Exercise: Study Protocol for a Multicenter Randomized Controlled Trial

improve overall survival among vulnerable lung cancer patients compared with standard care. Secondary outcomes include adherence to cancer treatment, symptom burden and health related quality of life.

cancer
lung carcinoma
lung cancer
  • 0 views
  • 19 Sep, 2022
  • 4 locations
A Phase 2/3, Multicenter, Randomized, Double-blind, Placebo-Controlled, Adaptive Design Study to Evaluate the Efficacy and Safety of MK-5475 in Adults With Pulmonary Arterial Hypertension

This is a two-part (Phase 2/Phase 3) study of MK-5475, an inhaled soluble guanylate cyclase stimulator, in participants with pulmonary arterial hypertension (PAH). The first part (Phase 2) will assess three different doses of MK-5475 compared to placebo in a base period of 12 weeks, followed by comparison of three …

left ventricular end-diastolic pressure
pulmonary arterial hypertension
heart disease
right heart catheterization
body mass index
  • 37 views
  • 15 Sep, 2022
  • 74 locations